ANI Pharmaceuticals, Inc. reports developments as a diversified biopharmaceutical company that develops, manufactures, and commercializes therapeutics through Rare Disease, Generics, and Brands businesses. Its Rare Disease portfolio includes Purified Cortrophin® Gel and ophthalmology products such as ILUVIEN® and YUTIQ®, while its generics portfolio includes products launched through FDA-approved abbreviated new drug applications.
ANI news commonly covers quarterly and annual financial results, guidance updates, product revenue trends, FDA approvals, generic product launches, clinical data publications, investor presentations, and capital allocation actions. Company updates also describe activity in ophthalmology, rheumatology, nephrology, neurology, and pulmonology, along with manufacturing and commercialization execution in the United States.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will announce its first quarter 2023 financial results on May 8, 2023. The results will be shared before market opening, followed by a conference call at 8:30 a.m. ET, hosted by President and CEO Nikhil Lalwani and CFO Stephen P. Carey. Investors can participate by calling 800-245-3047 or via a live webcast on the company’s website. A replay of the call will be available shortly after and last for two weeks. ANI Pharmaceuticals focuses on providing high-quality branded and generic pharmaceuticals, particularly for conditions with significant unmet medical needs. The company aims for sustainable growth through its Purified Cortrophin® Gel franchise and enhancing its generics portfolio.